Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis
Open accessThe DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and outcomes, leading to an expanding use in millions of patients worldwide. However, they can cause a spectrum of immune-related adverse events (irAEs). Essentially, any organs can be affected by irAEs, which have emerged as therapy-limiting side effects. In the kidneys, ICI-associated acute interstitial nephritis (ICI-AIN) leads to acute kidney injury (AKI) in 2%–5% of patients on ICI therapy. AKI associated with ICI therapy pathologically presents with AIN in nearly 90% of the cases, but the pathophysiology of ICI-AIN remains to be defined. The generation of autoreactive T cells in patients receiving AIN-inducible drugs, such as proton pump inhibitors (PPIs), is one of the leading theories, supported by a higher incidence of ICI-AIN in patients on these AIN-inducible drugs. In this review, we will discuss our understanding of the incidence, potential pathophysiological mechanisms, clinical presentations, risk factors, diagnosis, and management of PPI-related AIN and its interaction with ICI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Currently, four different classes of ICIs have been approved by the US Food and Drug Administration (FDA) for treatment of various cancers [1, 2], including anti-cytotoxic T lymphocyte–associated protein 4 (CTLA-4) (ipilimumab), anti-programmedcelldeathprotein1(PD-1)(cemiplimab,nivolumab, and…”
BackgroundPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109970 · Cited by 1,883 · cited 1×
“…T lymphocyte–associated protein 4 (CTLA-4) (ipilimumab), anti-programmedcelldeathprotein1(PD-1)(cemiplimab,nivolumab, and pembrolizumab), or PD-ligand 1 (PD-L1) (atezolizumab, avelumab, and durvalumab), and the most recent one antilym-phocyte activation gene-3 (LAG-3) (relatlimab) [3–6].”
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195 · cited 1×
“…T lymphocyte–associated protein 4 (CTLA-4) (ipilimumab), anti-programmedcelldeathprotein1(PD-1)(cemiplimab,nivolumab, and pembrolizumab), or PD-ligand 1 (PD-L1) (atezolizumab, avelumab, and durvalumab), and the most recent one antilym-phocyte activation gene-3 (LAG-3) (relatlimab) [3–6].”
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
Lazarus, B., Chen, Y., Wilson, F. P., Sang, Y., Chang, A. R., Coresh, J., & Grams, M. E. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.7193 · Cited by 729 · cited 1×
“A prospective epidemiologic study using the Atherosclerosis Risk in Communities database in the USA suggested a 31% increase of the risk for PPI-AIN in patients taking twice-daily dosages of PPIs compared to a single daily dosage [34].”
Method25 Years of Proton Pump Inhibitors: A Comprehensive Review
Strand, D. S., Kim, D., & Peura, D. A. (2017) · Gut and Liver · doi:10.5009/gnl15502 · Cited by 671 · cited 1×
“PPI is mainly used for treatment of acid-related disorders, such as peptic ulcer disease, GERD, erosive esophagitis, and Barrett’s esophagus [29].”
BackgroundClinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., Le, D. T., Lipson, E. J., Glezerman, I. G., Wolchok, J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.008 · Cited by 650
Praga, M., & González, E. (2010) · Kidney International · doi:10.1038/ki.2010.89 · Cited by 507
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., & Najafi, R. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27172 · Cited by 504 · cited 1×
“Blocking interaction of PD-1 and PD-L1 with anti-PD-1 or anti-PD-L1 monoclonal antibodies, respectively, promotes tumor cell apoptosis/death but also activates T cells or suppress their deactivation [54] (Fig.”
BackgroundDrug-induced acute interstitial nephritis
Rossert, J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.060002804.x · Cited by 488
González, E., Gutiérrez, E., Galeano, C., Chevia, C., de Sequera, P., Bernis, C., Parra, E. G., Delgado, R., Sanz, M., Ortiz, M., et al. (2008) · Kidney International · doi:10.1038/sj.ki.5002776 · Cited by 466 · cited 1×
“…study of 61 patients with biopsy-proven drug-induced AIN (mostly on antibiotics and NSAIDs), serum creatinine was lower in those treated with steroids; therefore, prompt treatment after diagnosis of AIN would avoid subsequent interstitial fibrosis and an incomplete recovery of renal function [93].”
BackgroundClinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study
Cortazar, F. B., Kibbelaar, Z. A., Glezerman, I. G., Abudayyeh, A., Mamlouk, O., Motwani, S. S., Murakami, N., Herrmann, S. M., Manohar, S., Shirali, A. C., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019070676 · Cited by 407 · cited 10×
“AKI caused by AIN is the major type of ICI-related renal irAEs, being observed in nearly 90% of kidney biopsies [7].”
BackgroundResultInfluentialSelf-citationSummary of Recommendation Statements
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.77 · Cited by 396
Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis
Eom, C.-S., Jeon, C. Y., Lim, J.-W., Cho, E.-G., Park, S. M., & Lee, K.-S. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.092129 · Cited by 393
Drug-induced acute interstitial nephritis
Perazella, M. A., & Markowitz, G. S. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.71 · Cited by 378
Acute interstitial nephritis: clinical features and response to corticosteroid therapy
Clarkson, M. R. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh485 · Cited by 343 · cited 1×
“Patients using high dose of PPI for prolonged duration may have a higher risk for AIN [38].”
BackgroundBiopsy-proven acute interstitial nephritis, 1993-2011: a case series
Muriithi, A. K., Leung, N., Valeri, A. M., Cornell, L. D., Sethi, S., Fidler, M. E., & Nasr, S. H. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.04.027 · Cited by 337 · cited 4×
“The study from the Mayo Clinic showed that patients with PPI-AIN tended to be older compared with antibiotic-or NSAID-related AIN [41].”
BackgroundInfluentialProton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD
Xie, Y., Bowe, B., Li, T., Xian, H., Balasubramanian, S., & Al-Aly, Z. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121377 · Cited by 337 · cited 2×
“A cohort study including 173321 new PPI users and 20270 H2RAs new users, both with normal renal function at baseline, indicated that compared to H2RAs, PPI significantly increased the risk of incident CKD, doubling of serum creatinine level, eGFR decline > 30%, and ESKD development by 28%–96% [32].”
BackgroundResultPharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept
Pichler, W. J. (2002) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/00130832-200208000-00003 · Cited by 309 · cited 1×
“Similar to superantigen stimulations, some drugs may directly interact with the T-cell receptor or the major histocompatibility peptide complex, leading to T-cell activation [63].”
BackgroundSeethapathy, H., Zhao, S., Chute, D. F., Zubiri, L., Oppong, Y., Strohbehn, I., Cortazar, F. B., Leaf, D. E., Mooradian, M. J., Villani, A.-C., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00990119 · Cited by 304 · cited 10×
“Two large retrospective studies suggested that PPI use caused a roughly 3-fold increase of the risk for ICI-AKI [4, 7].”
BackgroundInfluentialAnti-CTLA4 Antibody–Induced Lupus Nephritis
Fadel, F., Karoui, K. E., & Knebelmann, B. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904283 · Cited by 300 · cited 1×
“Additionally, minimal change disease, focal segmental glomerulosclerosis (FSGS), lupus nephritis, and renal vasculitis after ICIs therapy have been reported in several case reports [66–68].”
BackgroundCTLA-4: From mechanism to autoimmune therapy
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 297 · cited 1×
“This allows interaction of CD28 and CD80/CD86,resulting in T-cell activation [53].”
Mamlouk, O., Selamet, U., Machado, S., Abdelrahim, M., Glass, W. F., Tchakarov, A., Gaber, L., Lahoti, A., Workeneh, B., Chen, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0478-8 · Cited by 296
Haas, M., Spargo, B. H., Wit, E.-J. C., & Meehan, S. M. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70196-x · Cited by 269 · cited 1×
“Approximately 90% of patients with drug-induced AIN have tubular non-nephrotic level proteinuria, but a study suggested that older patients more likely had higher degree of proteinuria [74].”
BackgroundProton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
El Rouby, N., Lima, J. J., & Johnson, J. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461835 · Cited by 263 · cited 1×
“PPIs are a class of medications used to suppress acid production by irreversibly binding to the H + /K + ATPase pump on the secretory surface of the gastric parietal epithelial cells [26, 27].”
BackgroundProton-pump inhibitors and risk of fractures: an update meta-analysis
Zhou, B., Huang, Y., Li, H., Sun, W., & Liu, J. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3365-x · Cited by 252
Proton Pump Inhibitors: Review of Emerging Concerns
Nehra, A. K., Alexander, J. A., Loftus, C. G., & Nehra, V. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.10.022 · Cited by 248 · cited 3×
“Until the association of PPI and ICI-AIN is better clarified, it is reasonable to monitor serum creatinine and/or eGFR with each ICI dose, based on CKD guidelines for monitoring patients taking medications with potential nephrotoxicity [89, 94].”
BackgroundMethodResultAcute kidney injury in patients treated with immune checkpoint inhibitors
Gupta, S., Short, S. A. P., Sise, M. E., Prosek, J. M., Madhavan, S. M., Soler, M. J., Ostermann, M., Herrmann, S. M., Abudayyeh, A., Anand, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003467 · Cited by 236 · cited 8×
“It has been shown that duration of corticosteroids of 28 days or less is safe and has similar efficacious compared to longer durations for patients with ICI-AKI [8].”
BackgroundResultInfluentialSelf-citationXie, Y., Bowe, B., Yan, Y., Xian, H., Li, T., & Al-Aly, Z. (2019) · BMJ · doi:10.1136/bmj.l1580 · Cited by 228 · cited 1×
“Several large epidemiologic studies suggested that PPI use significantly increased the risk of incident chronic kidney disease (CKD), CKD progression, and kidney failure [32–35].”
BackgroundMcDonald, E. G., Milligan, J., Frenette, C., & Lee, T. C. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.42 · Cited by 216
Cheungpasitporn, W., Thongprayoon, C., Kittanamongkolchai, W., Srivali, N., Edmonds, P. J., Ungprasert, P., O'Corragain, O. A., Korpaisarn, S., & Erickson, S. B. (2015) · Renal Failure · doi:10.3109/0886022x.2015.1057800 · Cited by 215
Blank, M.-L., Parkin, L., Paul, C., & Herbison, P. (2014) · Kidney International · doi:10.1038/ki.2014.74 · Cited by 213 · cited 2×
“As such, PPIs have been recognized as an important cause of drug-induced AIN both in the general population and in cancer patients receiving ICIs [4, 7, 17].”
Ward, R. M., & Kearns, G. L. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0012-x · Cited by 202
Xie, Y., Bowe, B., Li, T., Xian, H., Yan, Y., & Al-Aly, Z. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.021 · Cited by 202 · cited 1×
“…showed that at time of AKI diagnosis, compared to non-ICI-AKI, serum C-reactive protein (CRP) was increased in ICI-AKI patients (median [IQR] 54.0 [33.7, 90.0] vs 3.5 [3.0, 7.9] mg/L, P 0.001), and urine retinol binding protein to urine creatinine ratio was also significantly elevated (median…”
BackgroundInfluentialAntoniou, T., Macdonald, E. M., Hollands, S., Gomes, T., Mamdani, M. M., Garg, A. X., Paterson, J. M., & Juurlink, D. N. (2015) · CMAJ Open · doi:10.9778/cmajo.20140074 · Cited by 199 · cited 3×
“Data from the Ontario population-based study indicated a ∼ 2.5-fold increase of AKI risk (13.49 vs 5.46 per 1000 person-years) among patients receiving PPIs compared to controls [14].”
BackgroundResultInfluentialSmelick, G. S., Heffron, T. P., Chu, L., Dean, B., West, D. A., DuVall, S. L., Lum, B. L., Budha, N., Holden, S. N., Benet, L. Z., et al. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400403s · Cited by 190 · cited 1×
“A large retrospective cross-sectional study reported that among cancer patients,up to 33% used acid-reducing agents,and PPIs were the most commonly prescribed drugs among this class of agents [10, 11].”
BackgroundProton Pump Inhibitors and Acute Interstitial Nephritis
Geevasinga, N., Coleman, P. L., Webster, A. C., & Roger, S. D. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.11.004 · Cited by 188 · cited 4×
“However, the eGFR remained significantly reduced both at 3 and 6 months after initial presentation when compared with the baseline, with a median reduction of 15.9 and 11.5 ml/min per 1.73 cm 2 , respectively [49].”
BackgroundResultInfluentialNochaiwong, S., Ruengorn, C., Awiphan, R., Koyratkoson, K., Chaisai, C., Noppakun, K., Chongruksut, W., & Thavorn, K. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw470 · Cited by 185 · cited 1×
“A recent meta-analysis including nine studies showed that among 2.6 million patients enrolled, 20% were PPI users,and the PPI use significantly increased the risk of AIN (relative risk ratio, 3.61; 95% CI, 2.37–5.51) [79].”
BackgroundInfluentialLong-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence
Cheung, K. S., & Leung, W. K. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819834511 · Cited by 177
Mechanisms of proton pump inhibitor‐induced hypomagnesemia
Gommers, L. M. M., Hoenderop, J. G. J., & de Baaij, J. H. F. (2022) · Acta Physiologica · doi:10.1111/apha.13846 · Cited by 167
Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease
Klatte, D. C. F., Gasparini, A., Xu, H., de Deco, P., Trevisan, M., Johansson, A. L. V., Wettermark, B., Ärnlöv, J., Janmaat, C. J., Lindholm, B., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.046 · Cited by 163 · cited 1×
“Recently, a graded association between cumulative PPI exposure and risk of CKD progression was revealed [86], suggesting that PPI use was significantly associated with high risk for both development and progression of CKD, and this association was more prominent in those taking high doses with long…”
BackgroundSystematic review: proton pump inhibitor‐associated acute interstitial nephritis
SIERRA, F., SUAREZ, M., REY, M., & VELA, M. F. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03407.x · Cited by 160 · cited 1×
“Some reports suggested that the second cause of drug-induced AIN was PPI use, accounting for 14%–64% [41, 47–51], and incidence of biopsy-proven AIN related to PPI has been increasing over the last decades [52].”
BackgroundProton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases
SIMPSON, I. J., MARSHALL, M. R., PILMORE, H., MANLEY, P., WILLIAMS, L., THEIN, H., & VOSS, D. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00651.x · Cited by 157 · cited 1×
“Another case series study including 15 patients with PPI-AIN observed that serum creatinine concentration was significantly higher (1.57 vs 0.94 mg/dl) at 3–18 months after PPI withdrawal than baseline [50].”
BackgroundInfluentialAcute Interstitial Nephritis: A Clinical and Morphological Study in 27 Patients
Buysen, J. G. M., Houthoff, H. J., Krediet, R. T., & Arisz, L. (1990) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/5.2.94 · Cited by 157
Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Moledina, D. G., Wilson, F. P., Pober, J. S., Perazella, M. A., Singh, N., Luciano, R. L., Obeid, W., Lin, H., Kuperman, M., Moeckel, G. W., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127456 · Cited by 154
Involvement of Drug-Specific T Cells in Acute Drug-Induced Interstitial Nephritis
Spanou, Z., Keller, M., Britschgi, M., Yawalkar, N., Fehr, T., Neuweiler, J., Gugger, M., Mohaupt, M., & Pichler, W. J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050418 · Cited by 151 · cited 2×
“A positive stain of either CD4 + or CD8 + T cells also has been revealed in kidney interstitial tissue [57, 60].”
BackgroundAcute interstitial nephritis due to omeprazole
Ruffenach, S. J., Siskind, M. S., & Lien, Y.-H. H. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90181-a · Cited by 133
Proton pump inhibitors and the kidney: critical review
Brewster, U. C., & Perazella, M. A. (2007) · Clinical Nephrology · doi:10.5414/cnp68065 · Cited by 129 · cited 3×
“PPI-related kidney adverse effects including AIN and AKI have been reported [12–18].”
BackgroundResultProton pump inhibitors and acute kidney injury: a nested case–control study
Klepser, D. G., Collier, D. S., & Cochran, G. L. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-150 · Cited by 126
Melloni, C., Washam, J. B., Jones, W. S., Halim, S. A., Hasselblad, V., Mayer, S. B., Heidenfelder, B. L., & Dolor, R. J. (2015) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.114.001177 · Cited by 122
Mechanisms of Drug-Induced Interstitial Nephritis
Raghavan, R., & Shawar, S. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.11.004 · Cited by 117 · cited 2×
“Peripher-ally, the drug-formed haptens are transported to kidney, where they are filtered, endocytosed, and metabolized by tubular epithelial cells [61].”
BackgroundImmune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
Herrmann, S. M., & Perazella, M. A. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.04.018 · Cited by 116 · cited 2×
“It is hypothesized that administration of drugs that potentially increase the risk of AIN may initiate the immune reaction triggered by drug-specific T cells in the setting of immunotherapy [5,57,58].”
BackgroundSelf-citationRizzo, A., Cusmai, A., Giovannelli, F., Acquafredda, S., Rinaldi, L., Misino, A., Montagna, E. S., Ungaro, V., Lorusso, M., & Palmiotti, G. (2022) · Cancers · doi:10.3390/cancers14061404 · Cited by 116
Torpey, N., Barker, T., & Ross, C. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh137 · Cited by 112 · cited 2×
“Some reports suggested that the second cause of drug-induced AIN was PPI use, accounting for 14%–64% [41, 47–51], and incidence of biopsy-proven AIN related to PPI has been increasing over the last decades [52].”
BackgroundIsik, B., Alexander, M. P., Manohar, S., Vaughan, L., Kottschade, L., Markovic, S., Lieske, J., Kukla, A., Leung, N., & Herrmann, S. M. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.01.013 · Cited by 112 · cited 9×
“We also found that use of PPI or other AIN-associated drugs led to a more rapid onset of AKI [36], suggesting that when PPIs are prescribed at the initiation of ICI therapy, these patients should be followed particularly closely for AKI events; however, larger prospective studies are needed to…”
BackgroundResultInfluentialSelf-citationPPIs and kidney disease: from AIN to CKD
Moledina, D. G., & Perazella, M. A. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0309-2 · Cited by 106 · cited 4×
“Regarding PPI-AIN, it has been reported that fever presents in less than half patients, rash in 10%, and eosinophilia in about one-third [28].”
BackgroundMethodResultInfluentialProton pump inhibitor‐induced acute interstitial nephritis
Härmark, L., Van Der Wiel, H. E., De Groot, M. C. H., & Van Grootheest, A. C. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02927.x · Cited by 103 · cited 1×
“A case series study showed that within 12 hours of re-exposure to pantoprazole, a patient developed symptoms of another episode of AIN [16].”
BackgroundCardiac Complications in Immune Checkpoint Inhibition Therapy
Tajiri, K., & Ieda, M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00003 · Cited by 103 · cited 1×
“ICI-related irAEs can occur in any organ at a substantially high frequency with a wide range from 59% to 85% overall [23], and with various degrees of severity from mild to life-threatening (Table 1).”
BackgroundLuo, H., Fan, Q., Xiao, S., & Chen, K. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3358-5 · Cited by 100 · cited 1×
“As one of the most frequently used classes of medications worldwide [30, 31], including among cancer patients [10], PPIs are generally thought to be safe, however, their use has been associated with a substantial adverse impact (Table 2).”
BackgroundProton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?
Fohl, A. L., & Regal, R. E. (2011) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v2.i3.17 · Cited by 97
Review: Acute tubulointerstitial nephritis
Toto, R. D. (1990) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199006000-00007 · Cited by 94
Medication-Induced Interstitial Nephritis in the 21st Century
Nast, C. C. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.11.016 · Cited by 88
Sherwood, M. W., Melloni, C., Jones, W. S., Washam, J. B., Hasselblad, V., & Dolor, R. J. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002245 · Cited by 83
(2015) · Iranian Journal of Kidney Diseases · Cited by 82
Hopkins, A. M., Kichenadasse, G., McKinnon, R. A., Abuhelwa, A. Y., Logan, J. M., Badaoui, S., Karapetis, C. S., Rowland, A., & Sorich, M. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01606-4 · Cited by 81 · cited 1×
“Notably, the use of PPIs has been associated with worse outcomes in the setting of ICI therapy in some [19–21], although not in all studies [22].”
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers, B., Leaf, D. E., Porta, C., Soler, M. J., & Perazella, M. A. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00630-8 · Cited by 81 · cited 1×
“It is hypothesized that administration of drugs that potentially increase the risk of AIN may initiate the immune reaction triggered by drug-specific T cells in the setting of immunotherapy [5,57,58].”
BackgroundRenal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors
Gallan, A. J., Alexander, E., Reid, P. D., Kutuby, F., Chang, A., & Henriksen, K. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.04.016 · Cited by 80 · cited 2×
“Kidney biopsies of patient with ICI-AIN have similar pattern, but may present with other findings such as FSGS, vasculitis, and, at times, granulomatous sarcoid-like lesions [36, 66, 69, 70].”
BackgroundManohar, S., Ghamrawi, R., Chengappa, M., Goksu, B. N. B., Kottschade, L. A., Finnes, H. D., Dronca, R. S., Leventakos, K., Herrmann, J., & Herrmann, S. M. (2020) · Kidney360 · doi:10.34067/kid.0000152019 · Cited by 79
Self-citationKoda, R., Watanabe, H., Tsuchida, M., Iino, N., Suzuki, K., Hasegawa, G., Imai, N., & Narita, I. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0848-y · Cited by 77 · cited 1×
“Aberrant activation of self-reactive T cells initiated by ICIs can reduce or disturb immune tolerance against renal antigens [55].”
BackgroundWijarnpreecha, K., Thongprayoon, C., Chesdachai, S., Panjawatanana, P., Ungprasert, P., & Cheungpasitporn, W. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4725-5 · Cited by 75 · cited 1×
“Consistently,a meta-analysis including five studies with 536902 participants showed that compared to H2RAs, the risk of CKD development in PPI users was increased by 29% (pooled RR, 1.29; 95% CI, 1.22–1.36) [85].”
InfluentialNivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report
Daanen, R. A., Maas, R. J. H., Koornstra, R. H. T., Steenbergen, E. J., van Herpen, C. M. L., & Willemsen, A. E. C. A. B. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000189 · Cited by 75
Makunts, T., Cohen, I. V., Awdishu, L., & Abagyan, R. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-39335-7 · Cited by 73 · cited 1×
“…4.2; 95% CI, 2.8–6.3), and those who received the following PPIs as monotherapy also significantly increased the AKI frequency: lansoprazole (OR, 10.8; 95% CI, 7–17), omeprazole (OR 5.8; 95% CI, 3.8–8.9), esomeprazole (OR, 3.3; 95% CI, 2.2–5), and pantoprazole (OR, 1.8; 95% CI, 1.01–3.3) [84].”
BackgroundInfluentialMolecular pathways driving omeprazole nephrotoxicity
Fontecha‐Barriuso, M., Martín‐Sánchez, D., Martinez-Moreno, J. M., Cárdenas-Villacrés, D. E., Carrasco, S., Sánchez-Niño, M. D., Ruiz‐Ortega, M., Ortíz, A., & Sanz, A. B. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101464 · Cited by 73 · cited 2×
“PPI-related kidney adverse effects including AIN and AKI have been reported [12–18].”
BackgroundFacing the Challenge of Drug-Induced Acute Interstitial Nephritis
Sanchez-Alamo, B., Cases-Corona, C., & Fernandez-Juarez, G. (2023) · Nephron · doi:10.1159/000525561 · Cited by 71 · cited 10×
“The resultant metabolites are presented to dendritic cells that are located in kidney interstitial tissue, leading to subsequent T-cell-mediated immune response [62].”
BackgroundInfluentialINOBVIOUS STROKE: A CAUSE OF DELIRIUM AND DEMENTIA
DUNNE, J. W., LEEDMAN, P. J., & EDIS, R. H. (1986) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1986.tb00034.x · Cited by 70 · cited 1×
“Notably, the use of PPIs has been associated with worse outcomes in the setting of ICI therapy in some [19–21], although not in all studies [22].”
Acute Interstitial Nephritis Due to Pantoprazole
Ra, A., & Tobe, S. W. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d085 · Cited by 69
Stein, C., Burtey, S., Mancini, J., Pelletier, M., Sallée, M., Brunet, P., Berbis, P., Grob, J., Honoré, S., Gaudy‐Marqueste, C., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa137 · Cited by 69 · cited 1×
“Available data indicated that the incidence of AKI in patients receiving ICIs was ∼ 17% [4, 9, 43–45].”
BackgroundGarcía-Carro, C., Bolufer, M., Bury, R., Castañeda, Z., Muñoz‐Couselo, E., Felip, E., Lorente, D., Carreras, M. J., Gabaldón, A., Agraz, I., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab034 · Cited by 68
Farooqui, N., Zaidi, M., Vaughan, L. E., McKee, T. D., Ahsan, E., Pavelko, K. D., Villasboas, J. C., Markovic, S. N., Taner, T., Leung, N., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.11.020 · Cited by 67 · cited 3×
“Recently, it has been shown that the abundance of specific immune cells (e.g. CD4 + memory T cells,T helper, and dendritic cells) was significantly increased in kidney tissues of patients with ICI-AIN [56].”
BackgroundInfluentialSelf-citationKelly, C. J., & Neilson, E. G. (1987) · The Journal of experimental medicine · doi:10.1084/jem.165.1.107 · Cited by 62 · cited 1×
“A positive stain of either CD4 + or CD8 + T cells also has been revealed in kidney interstitial tissue [57, 60].”
BackgroundDavison, A. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.suppl_7.12 · Cited by 57 · cited 1×
“Data from analysis of kidney biopsy registers and several large case series suggested that only a small portion, ∼ 2%–3%, developed AIN [28, 37–39].”
MethodUchiyama, A. A. T., Silva, P. A. I. A., Lopes, M. S. M., Yen, C. T., Ricardo, E. D., Mutão, T. S., Pimenta, J. R., Machado, L. M., Shimba, D. S., & Peixoto, R. D. (2021) · Current Oncology · doi:10.3390/curroncol28010076 · Cited by 57 · cited 2×
“As one of the most frequently used classes of medications worldwide [30, 31], including among cancer patients [10], PPIs are generally thought to be safe, however, their use has been associated with a substantial adverse impact (Table 2).”
BackgroundPeng, Y.-C., Lin, C.-L., Yeh, H.-Z., Chang, C.-S., Wu, Y.-L., & Kao, C.-H. (2016) · Medicine · doi:10.1097/md.0000000000003363 · Cited by 55 · cited 2×
“…that PPI use increased the risk of ESKD by 88%, with the highest adjusted OR of esomeprazole (1.69; 95% CI, 1.45–1.98) and pantoprazole (1.63; 95% CI, 1.39–1.90), followed by rabeprazole (1.36; 95% CI, 1.02–1.81), lansoprazole (1.23; 95% CI, 1.09–1.4), and omeprazole (1.14; 95% CI, 1.02–1.26) [87].”
BackgroundInfluentialSoluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
Sise, M. E., Wang, Q., Seethapathy, H., Moreno, D., Harden, D., Smith, R. N., Rosales, I. A., Colvin, R. B., Chute, S., Cornell, L. D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006222 · Cited by 48 · cited 2×
“Furthermore, systemic soluble interleukin-2 receptor (sIL-2R) has been found to be elevated in patients with ICI-AIN compared to ICI-treated controls and hemodynamic AKI controls (median 2.5-fold upper limit of normal vs 0.8-and 0.9-fold, P 0.001 and P = 0.008, respectively) [83].”
BackgroundResultInfluentialSelf-citationHerrmann, S. M., Alexander, M. P., Romero, M. F., & Zand, L. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.05.015 · Cited by 43
Self-citationRenal failure after omeprazole
Christensen, P. B., Albertsen, K., & Jensen, P. B. (1993) · The Lancet · doi:10.1016/0140-6736(93)92531-w · Cited by 42
Singh, S., Long, J. P., Tchakarov, A., Dong, Y., Yee, C., & Lin, J. S. (2022) · JCI Insight · doi:10.1172/jci.insight.165108 · Cited by 41
Recurrent acute interstitial nephritis on rechallenge with omeprazole
Assouad, M., Vicks, S. L., Pokroy, M., & Willcourt, R. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91945-3 · Cited by 37 · cited 1×
“Rechallenge with a PPI in patients who previously had PPI-AIN may more rapidly develop a new AIN [75–77].”
BackgroundShimamura, Y., Watanabe, S., Maeda, T., Abe, K., Ogawa, Y., & Takizawa, H. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-02008-1 · Cited by 37 · cited 1×
“Available data indicated that the incidence of AKI in patients receiving ICIs was ∼ 17% [4, 9, 43–45].”
BackgroundChute, D. F., Zhao, S. J., Strohbehn, I. A., Rusibamayila, N., Seethapathy, H. S., Lee, M. D., Zubiri, L., Gupta, S., Leaf, D. E., Rahma, O. E., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.05.012 · Cited by 37 · cited 2×
“%) eGFR decline sustained for > 90 days occurred in 20% of survivors who lived at least 5 years [88].”
BackgroundInfluentialMiao, J., Sise, M. E., & Herrmann, S. M. (2022) · Frontiers in Nephrology · doi:10.3389/fneph.2022.1017921 · Cited by 34
Self-citationDraibe, J. B., García-Carro, C., Martínez-Valenzuela, L., Agraz, I., Fulladosa, X., Bolufer, M., Tango, A., Torrás, J., & Soler, M. J. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa027 · Cited by 28 · cited 2×
“%) were on PPIs, with no information about how many were on PPIs in the ICI group [78].”
BackgroundInfluentialAntacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
Jun, T. W., Özbek, U., Dharmapuri, S., Hardy-Abeloos, C., Zhu, H., Lin, J.-Y., Personeni, N., Pressiani, T., Nishida, N., Lee, P., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211010937 · Cited by 26 · cited 1×
“Notably, the use of PPIs has been associated with worse outcomes in the setting of ICI therapy in some [19–21], although not in all studies [22].”
Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: PRO
Herrmann, S. M. (2021) · Kidney360 · doi:10.34067/kid.0003962021 · Cited by 17 · cited 1×
“This is particularly important when PPI or another AIN-associated drug is used in the setting of rechallenge with ICI therapy [95].”
BackgroundSelf-citationManagement of Drug-Associated Acute Interstitial Nephritis
Barreto, E. F., & Rule, A. D. (2020) · Kidney360 · doi:10.34067/kid.0000042019 · Cited by 16 · cited 1×
“Notably, as a new cause of AIN, ICIs have attracted more and more attention [46, 62, 80].”
BackgroundImmune Checkpoint Inhibitor–Associated Sarcoidosis Reaction in the Kidney: Case Report
Charkviani, M., & Herrmann, S. M. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100626 · Cited by 16
Self-citation[Acute interstitial nephritis associated with omeprazole therapy].
Torregrosa, E., Rovira, R. E., Calvo, C., Hernández‐Jaras, J., Maduell, F., & Garcia, H. (2004) · PubMed · Cited by 13
Littman, J., & Halil, R. (2016) · PubMed Central · Cited by 11
Immune Check Point Inhibitor–Associated Endothelialitis
Bobart, S. A., Owoyemi, I. O., Grande, J. P., Leung, N., & Herrmann, S. M. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.05.027 · Cited by 8 · cited 1×
“Kidney biopsies of patient with ICI-AIN have similar pattern, but may present with other findings such as FSGS, vasculitis, and, at times, granulomatous sarcoid-like lesions [36, 66, 69, 70].”
BackgroundSelf-citationProton-pump inhibitors and chronic kidney disease: Hidden consequences of an inappropriate drug use?
Schiffl, H. H., Al-Nemnem, E., & Lang, S. M. (2020) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.284005 · Cited by 6 · cited 2×
“Some reports suggested that the second cause of drug-induced AIN was PPI use, accounting for 14%–64% [41, 47–51], and incidence of biopsy-proven AIN related to PPI has been increasing over the last decades [52].”
BackgroundKee, T. Y. S. (2023) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789811283987_0020 · Cited by 5
[Proton pump inhibitor-induced nephrotoxicity].
Klatte, D. C. F., Wiegersma, J., Dekker, F. W., & Gansevoort, R. T. (2021) · PubMed · Cited by 2
Cited by
Herrmann, S. M., Abudayyeh, A., Gupta, S., Gudsoorkar, P., Klomjit, N., Motwani, S. S., Karam, S., Costa E Silva, V. T., Khalid, S. B., Anand, S., et al. (2025) · Kidney international · doi:10.1016/j.kint.2024.09.017 · Cited by 67
Self-citationMohan, A., Krisanapan, P., Tangpanithandee, S., Thongprayoon, C., Kanduri, S. R., Cheungpasitporn, W., & Herrmann, S. M. (2024) · American Journal of Nephrology · doi:10.1159/000538274 · Cited by 28
Self-citationMiao, J., Thongprayoon, C., Krisanapan, P., Buglioni, A., Craici, I. M., & Cheungpasitporn, W. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.09.026 · Cited by 18
“13-15 In our cohort, AIN related to ICIs has already surpassed that associated with NSAIDs.”
Self-citationStone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 15
“It is possible that this association may be specific to certain cancer types, as PPIs have also been reported to have a neutral or potentially beneficial effect on patient survival 144–146 .”
Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors
Laurent, L., Abbar, B., Bihan, K., Dumas, É., Jochum, F., Lebrun‐Vignes, B., Spano, J., Salem, J., Hamy, A., Reyal, F., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3721 · Cited by 13
Metadata
- Authors
- Miao, J., & Herrmann, S. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Herrmann, Sandra M
- Venue
- Clinical Kidney Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-05-15
- Volume
- 16
- Issue
- 11
- Pages
- 1834-1844
- ISSN
- 2048-8505 (ISSN-L)
- 2048-8513
- PMC
- PMC10616479
- OpenAlex
- W4382790817
- Cited by
- 31
- References
- 106
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 11 · 2023: 3
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Kidney Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Korea National Institute of Health (K08 DK118120)
- NIDDK
- CCaTS (UL1TR002377)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- immune checkpoint inhibitors, proton pump inhibitors, acute interstitial nephritis, immune-related adverse events, acute kidney injury, drug-induced nephrotoxicity, autoreactive T cells, pathophysiology, risk factors, diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.